BWM
VRTX icon

Biltmore Wealth Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Biltmore Wealth Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$978K Sell
1,871
-115
-6% -$58.9K 0.3% 31
2026
Q2 		$987K Buy
1,986
+281
+16% +$125K 0.31% 29
2026
Q1 		$761K Buy
+1,705
New +$795K 0.27% 32

Other funds holding VRTX

MSV
MN Services Vermogensbeheer The Hague, Netherlands $13.4B AUM 37.34% 1-Year Est. Return
AP
Atwood & Palmer Kansas City, Missouri $1.95B AUM 16% 1-Year Est. Return
VWM
Valley Wealth Managers Paramus, New Jersey $1.76B AUM 33.82% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return
GGS
Galvin Gaustad & Stein Scottsdale, Arizona $1.33B AUM 13.15% 1-Year Est. Return
SC
Sapient Capital Indianapolis, Indiana $7.44B AUM 23.27% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
LJHT
Laurie J. Hall Trustee $314M AUM 27.43% 1-Year Est. Return
CFG
Cooper Financial Group Irvine, California $1.26B AUM 21.18% 1-Year Est. Return

Biltmore Wealth Management's VRTX Position: Q3 2026 in Review

Biltmore Wealth Management reduced its Vertex Pharmaceuticals (VRTX) stake by 5.8% in Q3 2026, selling an estimated $58.9K and leaving 1,871 shares worth $978K. The position accounts for 0.3% of the portfolio, ranked #31.

Biltmore Wealth Management first reported a position in VRTX in Q1 2026 and has held it in 3 quarters since. The position peaked at $987K in Q2 2026. 66 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.

  • Biltmore Wealth Management held 1,871 shares of Vertex Pharmaceuticals worth $978K as of Q3 2026.
  • Biltmore Wealth Management sold 115 Vertex Pharmaceuticals shares in Q3 2026, an estimated $58.9K.
  • Vertex Pharmaceuticals made up 0.3% of Biltmore Wealth Management's portfolio in Q3 2026, its #31 holding.
  • Biltmore Wealth Management first reported a position in Vertex Pharmaceuticals in Q1 2026 and has held it in 3 quarters since.
  • Biltmore Wealth Management's Vertex Pharmaceuticals position peaked at $987K in Q2 2026.
  • 66 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.

Based on Biltmore Wealth Management's 13F filing for Q3 2026, filed 9 Oct 2026.